Idrinol, ampoules 100mg/ml, 5ml, 10pcs

Composition

Active ingredient:

meldonium dihydrate without adsorbed moisture-100 mg (in terms of meldonium anhydrous-80.21 mg);

excipients:

water for injection.

Pharmacological action

IDRINOL is a metabolism-enhancing drug, an analog of gamma-butyrobetaine. It suppresses gamma-butyrobetaine hydroxinase, inhibits carnitine synthesis and transport of long-chain fatty acids through cell membranes, and prevents the accumulation of activated forms of non-oxidized fatty acids-derivatives of acylcarnitine and acyl coenzyme A.

Under conditions of ischemia, it restores the balance of oxygen delivery and its consumption in cells, prevents disruption of ATP transport; at the same time, it activates glycolysis, which proceeds without additional oxygen consumption. As a result of a decrease in the carnitine concentration, gamma-butyrobetaine, which has vasodilating properties, is intensively synthesized. The mechanism of action determines the variety of its pharmacological effects: increased efficiency, reduction of symptoms of mental and physical overstrain, activation of tissue and humoral immunity, cardioprotective effect.

In the case of acute ischemic damage to the myocardium, it slows down the formation of a necrotic zone, shortens the rehabilitation period. In heart failure, it increases myocardial contractility, increases exercise tolerance, and reduces the frequency of angina attacks.

In acute and chronic ischemic disorders of the cerebral circulation, it improves blood circulation in the focus of ischemia, promotes blood redistribution in favor of the ischemic area. It is effective in vascular and dystrophic fundus pathology. It has a tonic effect on the central nervous system, eliminates functional disorders of the nervous system in patients with chronic alcoholism with withdrawal syndrome.

Indications

For oral or intravenous use: as part of the complex therapy of coronary heart disease (angina pectoris, myocardial infarction), chronic heart failure, dyshormonal cardiomyopathy; as part of the complex therapy of acute and chronic disorders of the cerebral circulation (strokes and cerebrovascular insufficiency); reduced performance, physical exertion (including athletes), postoperative period to accelerate rehabilitation; withdrawal syndrome in chronic alcoholism (in combination with specific therapy alcoholism).

For parabulbar use: acute retinal circulatory disorders, hemophthalmos and retinal hemorrhages of various etiologies, thrombosis of the central retinal vein and its branches, retinopathy of various etiologies (including diabetic and hypertensive) – only for parabulbar use.

Contraindications

Increased intracranial pressure (including venous outflow disorders, intracranial tumors), pregnancy, lactation (breastfeeding), hypersensitivity to meldonium.

Side effects

From the cardiovascular system: rarely-tachycardia, decrease or increase in blood pressure.

From the central nervous system: rarely-psychomotor agitation.

From the digestive system: rarely-dyspeptic disorders.

Allergic reactions: rarely-pruritus, rash, hyperemia of the skin, angioedema; very rarely-eosinophilia.

Other: very rare-general weakness.

Interaction

When used together, meldonium enhances the effect of antianginal drugs, some antihypertensive drugs, and cardiac glycosides.

With the simultaneous use of meldonium with nitroglycerin, nifedipine, alpha-blockers, antihypertensive agents and peripheral vasodilators, moderate tachycardia and arterial hypotension may develop (caution is required with these combinations).

How to take, course of use and dosage

Due to the possibility of developing an exciting effect, it is recommended to use in the first half of the day. The dose is set individually depending on the indications and route of use.

When taken orally, a single dose is 0.25-1 g, the frequency of use and duration of treatment depend on the indications.

When administered intravenously, the dose is 0.5-1 g 1 time/day, the duration of treatment depends on the indications.

Parabulbarno enter 0.5 ml of solution for injection with a concentration of 500 mg/5 ml for 10 days.

Overdose

Symptoms: reduced blood pressure, accompanied by headache, tachycardia, dizziness and general weakness.

Treatment: symptomatic

Special instructions

Idrinol is not a first-line drug for acute coronary syndrome.

Influence on the ability to drive motor vehicles and manage mechanisms:

There are no data on the adverse effects of Idrinol on the rate of psychomotor reactions.

Storage conditions

At a temperature not exceeding 25 °C

Shelf life

3 years

Active ingredient

Meldonium

Conditions of release from pharmacies

By prescription

Dosage form

solution for injection and infusion